Ludmila A. Belyakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ludmila A. Belyakova has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Dmitriy Sergeevich Lebedev
Almazov National Medical Research Center
2 shared publications - Elena A. Lyasnikova
Almazov National Medical Research Centre
2 shared publications - Evgeny Mikhaylov
Almazov National Medical Research Center
2 shared publications - I. M. Kim
Al-Farabi Kazakh National University
2 shared publications - M. A. Trukshina
Almazov National Medical Research Center
2 shared publications - M. L. Abramov
Almazov National Medical Research Center
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- Vol. 60 (5) , 70-87
Pharmacogenetic profile of the efficacy of agomelatine for stabilizing remission in patients with alcohol dependence and comorbid depressive disorders: results of a double-blind, randomized, placebo-controlled study
Alcohol dependence (AD) and depressive disorders (DD) exhibit a high level of comorbidity, significantly complicating treatment and worsening the clinical prognosis. The search for drugs that target the common pathogenetic mechanisms of these comorbid conditions is relevant. One such drug is agomelatine: an MT1 and MT2 melatonin receptor agonist and a 5-HT2C serotonin receptor antagonist. The identification of pharmacogenetic markers of agomelatine efficacy is an important goal in personalized therapy for comorbid AD and DD, as individual treatment response remains difficult to predict. Objective: To identify pharmacogenetic markers of agomelatine efficacy in patients with AD and comorbid DD. Materials and Methods. The pharmacogenetic study was conducted based on a 12-week, double-blind, randomized, placebo-controlled trial (N=100) of agomelatine efficacy in outpatients with AD and comorbid depression. The primary efficacy indicator was treatment retention, defined as the time (weeks) until discontinuation for any reason. The study’s genetic panel included 10 polymorphic loci in 8 genes: pharmacological targets of agomelatine — the melatonin receptors MT1 ( MTNR1A ) and MT2 ( MTNR1B ) and the serotonin receptor 5-HT2C ( HTR2C) , the gene encoding the cytochrome P450 enzyme CYP1A2 , which controls agomelatine pharmacokinetics, and key genes of the dopamine system (DRD2, ANKK1 ) and the endogenous opioid system ( OPRM1 , OPRK1 ). An analysis of associations between individual genetic variants and their combinations with the risk of early treatment discontinuation was performed within the dominant model in the agomelatine and placebo groups using Cox regression models. Hazard ratio (HR) with confidence intervals (CI) were calculated. Results. In the group of patients receiving agomelatine, an increased risk of early discontinuation of therapy, taking into account gender and age adjustment, was associated with carriage of the minor allele T rs2119882 in the MTNR1A gene [HR=2.25; 95%CI: (1.02–5.00); p=0.045], as well as with combinations of this variant with carriage of the minor allele A rs1800497 in the ANKK1 gene [HR=2.5; 95%CI: (1.16–5.61), p=0.019], the major genotype GG rs6275 in the DRD2 gene [HR=2.13; 95%CI: (1.02–4.46), p=0.045], the major genotype GG rs 10830963 in the MTNR1B gene [HR=2.10; 95%CI: (1.04–4.23), p=0.039], minor allele A rs2069514 in the CYP1A2*1C gene [HR=2.32; 95%CI: (1.01–5.35), p=0.048]. There was also an independent marker of the risk of dropping out of the therapy program in the form of a combination of minor alleles C rs762551 in the CYP1A2*1F gene and C rs6318 in the HTR2C gene [HR=3.32; 95%CI: (1.04–6.42), p=0.042]. No associations were found in the placebo group. Conclusion. The results of this study suggest that the pharmacogenetic response to agomelatine is polygenic in nature and is determined by the interaction of genes regulating the pharmacodynamics of the drug, its pharmacokinetics, and the neurobiological mechanisms of AD (reward cascade). The results of the study also might create a possibility to develop a polygenic pharmacogenetic panel that can be used for personalized approach to treatment of the patients with AD and comorbid depression with agomelatine.
- 31 October 2026
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- Vol. 60 (5) , 70-87
Open AccessPharmacogenetic profile of the efficacy of agomelatine for stabilizing remission in patients with alcohol dependence and comorbid depressive disorders: results of a double-blind, randomized, placebo-controlled study
Alcohol dependence (AD) and depressive disorders (DD) exhibit a high level of comorbidity, significantly complicating treatment and worsening the clinical prognosis. The search for drugs that target the common pathogenetic mechanisms of these comorbid conditions is relevant. One such drug is agomelatine: an MT1 and MT2 melatonin receptor agonist and a 5-HT2C serotonin receptor antagonist. The identification of pharmacogenetic markers of agomelatine efficacy is an important goal in personalized therapy for comorbid AD and DD, as individual treatment response remains difficult to predict. Objective: To identify pharmacogenetic markers of agomelatine efficacy in patients with AD and comorbid DD. Materials and Methods. The pharmacogenetic study was conducted based on a 12-week, double-blind, randomized, placebo-controlled trial (N=100) of agomelatine efficacy in outpatients with AD and comorbid depression. The primary efficacy indicator was treatment retention, defined as the time (weeks) until discontinuation for any reason. The study’s genetic panel included 10 polymorphic loci in 8 genes: pharmacological targets of agomelatine — the melatonin receptors MT1 ( MTNR1A ) and MT2 ( MTNR1B ) and the serotonin receptor 5-HT2C ( HTR2C) , the gene encoding the cytochrome P450 enzyme CYP1A2 , which controls agomelatine pharmacokinetics, and key genes of the dopamine system (DRD2, ANKK1 ) and the endogenous opioid system ( OPRM1 , OPRK1 ). An analysis of associations between individual genetic variants and their combinations with the risk of early treatment discontinuation was performed within the dominant model in the agomelatine and placebo groups using Cox regression models. Hazard ratio (HR) with confidence intervals (CI) were calculated. Results. In the group of patients receiving agomelatine, an increased risk of early discontinuation of therapy, taking into account gender and age adjustment, was associated with carriage of the minor allele T rs2119882 in the MTNR1A gene [HR=2.25; 95%CI: (1.02–5.00); p=0.045], as well as with combinations of this variant with carriage of the minor allele A rs1800497 in the ANKK1 gene [HR=2.5; 95%CI: (1.16–5.61), p=0.019], the major genotype GG rs6275 in the DRD2 gene [HR=2.13; 95%CI: (1.02–4.46), p=0.045], the major genotype GG rs 10830963 in the MTNR1B gene [HR=2.10; 95%CI: (1.04–4.23), p=0.039], minor allele A rs2069514 in the CYP1A2*1C gene [HR=2.32; 95%CI: (1.01–5.35), p=0.048]. There was also an independent marker of the risk of dropping out of the therapy program in the form of a combination of minor alleles C rs762551 in the CYP1A2*1F gene and C rs6318 in the HTR2C gene [HR=3.32; 95%CI: (1.04–6.42), p=0.042]. No associations were found in the placebo group. Conclusion. The results of this study suggest that the pharmacogenetic response to agomelatine is polygenic in nature and is determined by the interaction of genes regulating the pharmacodynamics of the drug, its pharmacokinetics, and the neurobiological mechanisms of AD (reward cascade). The results of the study also might create a possibility to develop a polygenic pharmacogenetic panel that can be used for personalized approach to treatment of the patients with AD and comorbid depression with agomelatine.
- Open Access
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 408-418
Optimization of the First-Line Therapy in Primary Mediastinal (Thymic) Large B-Cell Lymphoma
BACKGROUND. The standard first-line therapies for primary mediastinal (thymic) large B-cell lymphoma (PMBCL) have not yet been clearly defined. This is a rare disease (2–4 % among all NHLs), which makes it challenging to enroll patients into large randomized studies. Most commonly, induction therapy with DA-EPOCH-R and R-CHOP regimens is used, however, no explicit advantage of one of them over the other was demonstrated by any clinical study. The role of radiotherapy (RT) in the treatment of newly diagnosed PMBCL also remains a subject to debate. Besides, there are alternative options which have proven to be effective by smaller retrospective studies, in particular, consolidation of antitumor response by high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (auto-HSCT). AIM. To evaluate the outcomes of the first-line therapy with the standard DA-EPOCH-R and R-CHOP regimens as well as to study the feasibility of consolidating the achieved antitumor response by means of RT or HDCT with auto-HSCT in patents with newly diagnosed PMBCL in a real-world setting at one medical institution. MATERIALS & METHODS. This single-center cohort retrospective study enrolled 180 patients treated at the NN Petrov National Medical Cancer Research Center from 2013 to 2023. Most patients (n = 159) received therapy with DA-EPOCH-R regimen, R-CHOP was administered to fewer patients (n = 21). After achieving complete (CR) or partial response (PR) resulting from 6 drug therapy cycles and documented by PET/CT, patients either continued to be followed-up (n = 52) or received HDCT consolidation with auto-HSCT (n = 13) or RT (n = 64). The decision-making about the consolidation regimen was arbitrary, on researcher’s opinion. HDCT with auto-HSCT was most commonly administered to patients with stage III/IV and high IPI; RT was commonly used in patients with PR when the biopsy of the residual lesion with increased FDG uptake was technically impossible. RESULTS. In the total group, overall response rate was 76.7 % (138/180): CR 59.5 % and PR 17.2 %; in 23.3 % of cases primary refractoriness of the disease was reported. With the median follow-up of 29 months (range 17–56 months), progression-free survival (PFS) was 70.0 % and overall survival (OS) was 86.1 %. By univariate analysis of long-term outcomes, neither consolidation nor the lack of it affected PFS, which accounted for 92.3 % (HDCT with auto-HSCT), 95.3 % (RT), and 90.4 % (follow-up), respectively (p = 0.29). The evaluation of OS with and without consolidation yielded significant differences: 84.6 %, 96.9 %, and 96,2 %, respectively (p = 0.023), however, the multivariate analysis proved these data to be not significant (p = 0.06). CONCLUSION. The results of this study demonstrate the efficacy of DA-EPOCH-R regimen for PMBCL patients. After achieving CR or PR, often morphologically negative antitumor response, resulting from 6 DA-EPOCH-R cycles, the consolidation of the effect by means of RT or HDCT with auto-HSCT does not improve long-term survival rates.
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 408-418
Open AccessOptimization of the First-Line Therapy in Primary Mediastinal (Thymic) Large B-Cell Lymphoma
BACKGROUND. The standard first-line therapies for primary mediastinal (thymic) large B-cell lymphoma (PMBCL) have not yet been clearly defined. This is a rare disease (2–4 % among all NHLs), which makes it challenging to enroll patients into large randomized studies. Most commonly, induction therapy with DA-EPOCH-R and R-CHOP regimens is used, however, no explicit advantage of one of them over the other was demonstrated by any clinical study. The role of radiotherapy (RT) in the treatment of newly diagnosed PMBCL also remains a subject to debate. Besides, there are alternative options which have proven to be effective by smaller retrospective studies, in particular, consolidation of antitumor response by high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (auto-HSCT). AIM. To evaluate the outcomes of the first-line therapy with the standard DA-EPOCH-R and R-CHOP regimens as well as to study the feasibility of consolidating the achieved antitumor response by means of RT or HDCT with auto-HSCT in patents with newly diagnosed PMBCL in a real-world setting at one medical institution. MATERIALS & METHODS. This single-center cohort retrospective study enrolled 180 patients treated at the NN Petrov National Medical Cancer Research Center from 2013 to 2023. Most patients (n = 159) received therapy with DA-EPOCH-R regimen, R-CHOP was administered to fewer patients (n = 21). After achieving complete (CR) or partial response (PR) resulting from 6 drug therapy cycles and documented by PET/CT, patients either continued to be followed-up (n = 52) or received HDCT consolidation with auto-HSCT (n = 13) or RT (n = 64). The decision-making about the consolidation regimen was arbitrary, on researcher’s opinion. HDCT with auto-HSCT was most commonly administered to patients with stage III/IV and high IPI; RT was commonly used in patients with PR when the biopsy of the residual lesion with increased FDG uptake was technically impossible. RESULTS. In the total group, overall response rate was 76.7 % (138/180): CR 59.5 % and PR 17.2 %; in 23.3 % of cases primary refractoriness of the disease was reported. With the median follow-up of 29 months (range 17–56 months), progression-free survival (PFS) was 70.0 % and overall survival (OS) was 86.1 %. By univariate analysis of long-term outcomes, neither consolidation nor the lack of it affected PFS, which accounted for 92.3 % (HDCT with auto-HSCT), 95.3 % (RT), and 90.4 % (follow-up), respectively (p = 0.29). The evaluation of OS with and without consolidation yielded significant differences: 84.6 %, 96.9 %, and 96,2 %, respectively (p = 0.023), however, the multivariate analysis proved these data to be not significant (p = 0.06). CONCLUSION. The results of this study demonstrate the efficacy of DA-EPOCH-R regimen for PMBCL patients. After achieving CR or PR, often morphologically negative antitumor response, resulting from 6 DA-EPOCH-R cycles, the consolidation of the effect by means of RT or HDCT with auto-HSCT does not improve long-term survival rates.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 178-187
Cognitive effects of perampanel assessed by the EpiTrack Junior Test in school-aged children with epilepsy
Objective. To evaluate the impact of add-on perampanel on cognitive functions in school-aged children with epilepsy using the EpiTrack Junior test. Material and methods. Seventy-five patients aged 6—18 years were assessed before and 2 months after reaching a stable perampanel dose. They are divided into 2 groups according to the inclusion period (before 2023 and after 2023) due to the emergence of new literature data on the drug’s specific effectiveness in early adjuvant therapy after 2023. The 1st retrospective group consisted of 49 patients, most of whom were prescribed perampanel as a 4th—6th drug (54%). The 2nd prospective group consisted of 26 patients, most of whom (65%) were prescribed perampanel as a 2nd—3rd drug. Changes in total and subtest scores were analyzed versus diagnosis, sex, seizure-onset age, pharmacoresistance and EEG. Results. 66 patients completed the study. A significant increase in total EpiTrack score was observed (p<0.05) with positive correlation to seizure-onset age. Seizure reduction ≥50 % occurred in 68% and EEG improved in 40.9%. Reversible adverse events were reported in 25.8%. No statistically significant differences were found between the groups for any of these factors Conclusion. Adjunctive perampanel improves executive functions and is well tolerated in school-aged children with epilepsy.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 178-187
Cognitive effects of perampanel assessed by the EpiTrack Junior Test in school-aged children with epilepsy
Objective. To evaluate the impact of add-on perampanel on cognitive functions in school-aged children with epilepsy using the EpiTrack Junior test. Material and methods. Seventy-five patients aged 6—18 years were assessed before and 2 months after reaching a stable perampanel dose. They are divided into 2 groups according to the inclusion period (before 2023 and after 2023) due to the emergence of new literature data on the drug’s specific effectiveness in early adjuvant therapy after 2023. The 1st retrospective group consisted of 49 patients, most of whom were prescribed perampanel as a 4th—6th drug (54%). The 2nd prospective group consisted of 26 patients, most of whom (65%) were prescribed perampanel as a 2nd—3rd drug. Changes in total and subtest scores were analyzed versus diagnosis, sex, seizure-onset age, pharmacoresistance and EEG. Results. 66 patients completed the study. A significant increase in total EpiTrack score was observed (p<0.05) with positive correlation to seizure-onset age. Seizure reduction ≥50 % occurred in 68% and EEG improved in 40.9%. Reversible adverse events were reported in 25.8%. No statistically significant differences were found between the groups for any of these factors Conclusion. Adjunctive perampanel improves executive functions and is well tolerated in school-aged children with epilepsy.
- Open Access
- 24 February 2025
- Published by ECO-Vector LLC in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 12 (1) , 92-105
Clinical and diagnostic significance of risk factors for histopathologically confirmed uterine rupture after Сesarean section
BACKGROUND: Attempts to predict the outcomes of vaginal delivery in women with a uterine scar after cesarean section using highly informative predictors and prognostic models remain highly relevant. AIM: To demonstrate the significance of antenatal risk assessment for histopathologically confirmed uterine rupture using a scoring system in women with a uterine scar after cesarean section. MATERIALS AND METHODS: A retrospective multicenter comparative study was conducted on pregnancy and delivery records of 288 patients with a uterine scar after cesarean section. Antenatal risk assessment for histopathologically confirmed uterine rupture was performed using a clinical scoring system (≥5 points=high risk; 5 points=low risk). Group 1 included 135 patients (≥5 points) who underwent elective cesarean delivery; group 2 included 57 patients (5 points) who underwent elective cesarean section due to obstetric indications; group 3 included 66 patients (5 points) who delivered vaginally. Group 4 (n=27) was formed to assess the probability of histopathologically confirmed uterine rupture and included cases of scar rupture after cesarean section. The predictive quality of the scoring system was evaluated using ROC analysis, and the significance of each criterion was assessed in relation to uterine rupture. Histopathological examination of the myometrium from the lower uterine segment was performed. RESULTS: No significant differences in perinatal outcomes were observed among groups 1, 2, and 3. Factors significantly associated with uterine rupture (p 0.0001) included emergency cesarean section, anemia during pregnancy and the postoperative period, pathological blood loss (1000 mL), and two or more previous cesarean sections. ROC analysis demonstrated a sensitivity of 77.8%, specificity of 95.5%, and accuracy of 83.7%, indicating an excellent predictive quality of the scoring system. The optimal cutoff point was determined to be 6.5. CONCLUSION: The scoring system accurately predicts histopathologically confirmed uterine rupture, as validated by histopathological examination. A high risk of histopathologically confirmed uterine rupture along the scar following cesarean section is associated with a score of 6 or higher.
- 24 February 2025
- Published by ECO-Vector LLC in V.F.Snegirev Archives of Obstetrics and Gynecology
- Vol. 12 (1) , 92-105
Open AccessClinical and diagnostic significance of risk factors for histopathologically confirmed uterine rupture after Сesarean section
BACKGROUND: Attempts to predict the outcomes of vaginal delivery in women with a uterine scar after cesarean section using highly informative predictors and prognostic models remain highly relevant. AIM: To demonstrate the significance of antenatal risk assessment for histopathologically confirmed uterine rupture using a scoring system in women with a uterine scar after cesarean section. MATERIALS AND METHODS: A retrospective multicenter comparative study was conducted on pregnancy and delivery records of 288 patients with a uterine scar after cesarean section. Antenatal risk assessment for histopathologically confirmed uterine rupture was performed using a clinical scoring system (≥5 points=high risk; 5 points=low risk). Group 1 included 135 patients (≥5 points) who underwent elective cesarean delivery; group 2 included 57 patients (5 points) who underwent elective cesarean section due to obstetric indications; group 3 included 66 patients (5 points) who delivered vaginally. Group 4 (n=27) was formed to assess the probability of histopathologically confirmed uterine rupture and included cases of scar rupture after cesarean section. The predictive quality of the scoring system was evaluated using ROC analysis, and the significance of each criterion was assessed in relation to uterine rupture. Histopathological examination of the myometrium from the lower uterine segment was performed. RESULTS: No significant differences in perinatal outcomes were observed among groups 1, 2, and 3. Factors significantly associated with uterine rupture (p 0.0001) included emergency cesarean section, anemia during pregnancy and the postoperative period, pathological blood loss (1000 mL), and two or more previous cesarean sections. ROC analysis demonstrated a sensitivity of 77.8%, specificity of 95.5%, and accuracy of 83.7%, indicating an excellent predictive quality of the scoring system. The optimal cutoff point was determined to be 6.5. CONCLUSION: The scoring system accurately predicts histopathologically confirmed uterine rupture, as validated by histopathological examination. A high risk of histopathologically confirmed uterine rupture along the scar following cesarean section is associated with a score of 6 or higher.
- Open Access
- 17 February 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (1) , 4035
Dynamics of heart failure markers and cardiac reverse remodeling in patients receiving cardiac contractility modulation therapy
Динамика маркеров выраженности хронической сердечной недостаточности и обратное ремоделирование миокарда на фоне модуляции сердечной сократимости
- 17 February 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (1) , 4035
Open AccessDynamics of heart failure markers and cardiac reverse remodeling in patients receiving cardiac contractility modulation therapy
Динамика маркеров выраженности хронической сердечной недостаточности и обратное ремоделирование миокарда на фоне модуляции сердечной сократимости
- Open Access
- 15 August 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (7) , 3853
Two-year follow-up of patients with heart failure with reduced ejection fraction receiving cardiac contractility modulation
Aim. To assess the 2-year prognosis of patients with heart failure with reduced ejection fraction (HFrEF) receiving cardiac contractility modulation (CCM).Material and methods. This single-center observational study included 55 patients (46 men, mean age 53±11 years) with NYHA class II-III HFrEF receiving optimal medical therapy, with sinus rhythm, QRS styear and every 6 months during the 2ndyear of observation. The primary composite endpoint was mortality and heart transplantation. Secondary composite endpoints included death, heart transplantation, paroxysmal ventricular tachycardia/ ventricular fibrillation, hospitalizations due decompensated HFResults.The one-year and two-year survival rate was 95% and 80%, respectively. Primary endpoint was observed in 20% of patients. NYHA class III and higher levels of N-terminal pro-brain natriuretic peptide (NTproBNP) were associated with unfavorable prognosis (p=0,014 and p=0,026, respectively). NTproBNP was an independent predictor of survival (p=0,018). CCM contributed to a significant decrease in hospitalizations due to decompensated HF (pstyear. The predictor for the secondary composite endpoint was NTproBNP (p=0,047).Conclusion. CCM is associated with a significant decrease in hospitalization rate due to decompensated HF. The 2-year survival rate of patients with NYHA class II-III HF receiving CCM was 80%. The NTproBNP level was an independent predictor of survival in patients receiving CMM for 2 years. Further longer-term studies of the CCM efficacy are required.
- 15 August 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (7) , 3853
Open AccessTwo-year follow-up of patients with heart failure with reduced ejection fraction receiving cardiac contractility modulation
Aim. To assess the 2-year prognosis of patients with heart failure with reduced ejection fraction (HFrEF) receiving cardiac contractility modulation (CCM).Material and methods. This single-center observational study included 55 patients (46 men, mean age 53±11 years) with NYHA class II-III HFrEF receiving optimal medical therapy, with sinus rhythm, QRS styear and every 6 months during the 2ndyear of observation. The primary composite endpoint was mortality and heart transplantation. Secondary composite endpoints included death, heart transplantation, paroxysmal ventricular tachycardia/ ventricular fibrillation, hospitalizations due decompensated HFResults.The one-year and two-year survival rate was 95% and 80%, respectively. Primary endpoint was observed in 20% of patients. NYHA class III and higher levels of N-terminal pro-brain natriuretic peptide (NTproBNP) were associated with unfavorable prognosis (p=0,014 and p=0,026, respectively). NTproBNP was an independent predictor of survival (p=0,018). CCM contributed to a significant decrease in hospitalizations due to decompensated HF (pstyear. The predictor for the secondary composite endpoint was NTproBNP (p=0,047).Conclusion. CCM is associated with a significant decrease in hospitalization rate due to decompensated HF. The 2-year survival rate of patients with NYHA class II-III HF receiving CCM was 80%. The NTproBNP level was an independent predictor of survival in patients receiving CMM for 2 years. Further longer-term studies of the CCM efficacy are required.
- 6 February 2019
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 23 (1) , 60-66-66
THYROID DYSFUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
It is known that patients with chronic kidney disease (CKD) often have hypothyroidism. In patients with CKD, iodine excretion in the urine is disrupted. The high content of iodine in the thyroid gland and tissues leads to a disruption in the synthesis and peripheral metabolism of thyroid hormones. In hypothyroidism, there is a disruption of sodium and water reabsorption in the proximal tubule, the volume of the filtrate increases, the volume of the tubular apparatus overloads, and the eGFR decreases.TH Е AIM:to study the occurrence of hypothyroidism in patients with different stages of CKD, to evaluate the parameters of thyroid status and antithyroid antibodies in patients with CKD.PATIENTS AND METHODS.953 patients from I.P. Pavlov SPbSMU clinics (screening group) were examined. TSH, free T4, serum creatinine were defined and eGFR was calculated using the formula CKD-EPI in all patients. A group of patients with hypothyroidism accounted for 466 patients. Patients with a normal TSH of 0.4-2.5 mIU / L (comparison group) were selected from the screening group.RESULTS.eGFR in the screening group and in the group of hypothyroid patients correlated with age. Hypothyroidism was associated with female sex and older age. In the group of patients with advanced stage CKD (3B-5), the incidence of subclinical and manifest hypothyroidism was 3 times higher than in the group with normal GFR (GFR> 90 ml / min, p = 0.007). In the group of patients with hypothyroidism, the frequency of advanced stages of CKD (3B-5) was 2 times higher than in the comparison group (p = 0.02). In patients with CKD, a direct correlation was found between GFR and free T3 (r = 0.34, p = 0.02). Thyroid peroxidase antibodies were revealed in 64% of patients with CKD with hypothyroidism.CONCLUSION.Hypothyroidism is associated with chronic kidney disease. For patients with CKD, there is a syndrome of euthyroid pathology ("low T3" syndrome). Hypothyroidism in patients with CKD is not always the outcome of autoimmune thyroiditis.
- 6 February 2019
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 23 (1) , 60-66-66
THYROID DYSFUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
It is known that patients with chronic kidney disease (CKD) often have hypothyroidism. In patients with CKD, iodine excretion in the urine is disrupted. The high content of iodine in the thyroid gland and tissues leads to a disruption in the synthesis and peripheral metabolism of thyroid hormones. In hypothyroidism, there is a disruption of sodium and water reabsorption in the proximal tubule, the volume of the filtrate increases, the volume of the tubular apparatus overloads, and the eGFR decreases.TH Е AIM:to study the occurrence of hypothyroidism in patients with different stages of CKD, to evaluate the parameters of thyroid status and antithyroid antibodies in patients with CKD.PATIENTS AND METHODS.953 patients from I.P. Pavlov SPbSMU clinics (screening group) were examined. TSH, free T4, serum creatinine were defined and eGFR was calculated using the formula CKD-EPI in all patients. A group of patients with hypothyroidism accounted for 466 patients. Patients with a normal TSH of 0.4-2.5 mIU / L (comparison group) were selected from the screening group.RESULTS.eGFR in the screening group and in the group of hypothyroid patients correlated with age. Hypothyroidism was associated with female sex and older age. In the group of patients with advanced stage CKD (3B-5), the incidence of subclinical and manifest hypothyroidism was 3 times higher than in the group with normal GFR (GFR> 90 ml / min, p = 0.007). In the group of patients with hypothyroidism, the frequency of advanced stages of CKD (3B-5) was 2 times higher than in the comparison group (p = 0.02). In patients with CKD, a direct correlation was found between GFR and free T3 (r = 0.34, p = 0.02). Thyroid peroxidase antibodies were revealed in 64% of patients with CKD with hypothyroidism.CONCLUSION.Hypothyroidism is associated with chronic kidney disease. For patients with CKD, there is a syndrome of euthyroid pathology ("low T3" syndrome). Hypothyroidism in patients with CKD is not always the outcome of autoimmune thyroiditis.